When Using Foreign Clinical Data, Be Prepared To Prove U.S. Applicability
Executive Summary
When using data from clinical trials conducted outside the U.S. for an NDA, drug makers must be able to demonstrate that the data are applicable to the U.S. population and U.S. medical practice, Murray Lumpkin, FDA's deputy commissioner for international programs, said
You may also be interested in...
Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection
Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S
Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection
Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S
Multi-Regional Trials Prompt FDA Interest In Sponsors' Trial Infrastructure Decisions
The need to ensure data quality necessitates a better understanding of how the data was collected, CDER's Robert O'Neill tells DIA.